Conservative Management of Overanticoagulation in Patients With Low–Moderate Risk for Bleeding Complications

Clinical and Applied Thrombosis/Hemostasis

Volumn 24, Issue 8, 2018, Pages 1255-1260

  Schapkaitz, Elise ^a   Louw, Susan ^a   Friedman, Jessica ^b   Sithole, Johanna ^b   Masebe, Mavis ^b   Jacobson, Barry F ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

Author keywords

anticoagulation clinic; bleeding; INR monitoring; warfarin

Indexed keywords

VITAMIN K GROUP; WARFARIN; ANTICOAGULANT AGENT;

ADULT; AGED; ANTICOAGULATION; ARTERY EMBOLISM; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CONSERVATIVE TREATMENT; DIABETES MELLITUS; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEART VALVE REPLACEMENT; HEMATOCRIT; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; OVERANTICOAGULATION; PRIORITY JOURNAL; RISK FACTOR; VENOUS THROMBOEMBOLISM; AMBULATORY CARE; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; MIDDLE AGED;

ADULT; AGED; AMBULATORY CARE; ANTICOAGULANTS; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; RISK FACTORS;

EID: 85048998972     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029618783250     Document Type: Article

References (18)

1. Panneerselvam S, Baglin C, Lefort W, Baglin T. Analysis of risk factors for over-anticoagulation in patients receiving long-term warfarin. Br J Haematol. 1998;103(2):422–424
2. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994;120(11):897–902
3. Kearon C, Akl EA, Ornelas J. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–352
4. Crowther MA, Garcia D, Ageno W. Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10. Results of a prospective cohort study. Thromb Haemost. 2010;104(1):118–121
5. Crowther MA, Donovan D, Harrison L, McGinnis J, Ginsberg J. Low-dose oral vitamin K reliably reverses over-anticoagulation due to warfarin. Thromb Haemost. 1998;79(6):1116–1118
6. Hylek EM, Chang YC, Skates SJ, Hughes RA, Singer DE. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med. 2000;160(11):1612–1617
7. Schapkaitz E, Sithole J. Predictors of warfarin dose requirements in South African patients attending an anticoagulation clinic. J Vasc Nurs. 2017;35(1):27–30
8. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105(2):91–99
9. Wells PS, Forgie MA, Simms M. The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. Arch Intern Med. 2003;163(8):917–20
10. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and=Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–694
11. Berger R, Salhanick SD, Chase M, Ganetsky M. Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin. Ann Emerg Med. 2013;61(4):475–479
12. Bleker SM, Brekelmans MPA, Eerenberg ES. Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. An individual patient data meta-analysis. Thromb Haemost. 2017;117(10):1944–1951
13. Majeed A, Hwang HG, Connolly SJ. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation. 2013;128(21):2325–2332
14. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–1100
15. Garcia DA, Regan S, Crowther M, Hylek EM. The risk of hemorrhage among patients with warfarin-associated coagulopathy. J Am Coll Cardiol. 2006;47(4):804–808
16. Di Nisio M, Raskob G, Buller HR. Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists. Thromb Haemost. 2017;117(4):784–793
17. Crowther MA, Ageno W, Garcia D. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med. 2009;150(5):293–300
18. Ageno W, Garcia D, Silingardi M, Galli M, Crowther M. A randomized trial comparing 1mg of oral vitamin K with no treatment in the management of warfarin-associated coagulopathy in patients with mechanical heart valves. J Am Coll Cardiol. 2005;46(4):732–733